The Food and Drug Administration Friday issued emergency use authorizations to Xiamen Biotime Biotechnology Co. and Access Bio Inc. for serology-based tests to detect SARS-CoV-2 antibodies indicating recent or prior infection.

The tests are approved for use by laboratories certified under the Clinical Laboratory Improvement Amendments that meet requirements to perform moderate or high complexity tests.

Related News Articles

Headline
The Food and Drug Administration yesterday released FAQs describing the procedures for importing respirators, face masks, and other personal protective…
Headline
The departments of Health and Human Services and Defense will pay Moderna Inc. about $1.5 billion to produce and deliver 100 million doses of its COVID-19…
Headline
The Department of Health and Human Services yesterday announced it has expanded the providers eligible for its Public Health and Social Services Emergency Fund…
Headline
Houston’s Kindred Healthcare and TIRR Memorial Hermann are among the many post-acute care providers that have incurred increased costs to prepare for and treat…
Headline
The Food and Drug Administration Friday authorized the emergency use of George Washington University Public Health Laboratory’s GWU SARS-CoV-2 RT-PCR Test. The…
Headline
Researchers have launched two clinical trials to test whether monoclonal (laboratory-made) antibodies can safely prevent SARS-CoV-2 infection or symptoms in…